View Item 

Show simple item record

Aclacinomycin A in the treatment of multiple myeloma: A Southwest Oncology Group study
dc.contributor.authorKaranes, Chatchadaen_US
dc.contributor.authorCrowley, Johnen_US
dc.contributor.authorSawkar, Laxmidasen_US
dc.contributor.authorTranum, Bill L.en_US
dc.contributor.authorHicks, William J.en_US
dc.contributor.authorBonnet, John D.en_US
dc.contributor.authorDabich, Lyubicaen_US
dc.contributor.authorDana, Bruce W.en_US
dc.contributor.authorSalmon, Sydneyen_US
dc.date.accessioned2006-09-11T15:56:34Z
dc.date.available2006-09-11T15:56:34Z
dc.date.issued1990-02en_US
dc.identifier.citationKaranes, Chatchada; Crowley, John; Sawkar, Laxmidas; Tranum, Bill L.; Hicks, William J.; Bonnet, John D.; Dabich, Lyubica; Dana, Bruce W.; Salmon, Sydney; (1990). "Aclacinomycin A in the treatment of multiple myeloma: A Southwest Oncology Group study." Investigational New Drugs 8(1): 101-104. <http://hdl.handle.net/2027.42/45336>en_US
dc.identifier.issn0167-6997en_US
dc.identifier.issn1573-0646en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/45336
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2188925&dopt=citationen_US
dc.description.abstractFifty-two patients with progressive resistant multiple myeloma were entered in this Southwest Oncology Group Phase II study, using weekly intravenous Aclacinomycin A. Of forty-three evaluable patients for response, there was one partial remission of 2 years duration and two sustained clinical improvements with 25% reduction in paraprotein. Major toxicity seen was severe myelosuppression and significant nausea and vomiting requiring dose reduction and delay of the scheduled treatment. Cardiac arrhythmia was seen in one patient. Chronic daily schedule or continuous IV infusion is recommended for future study.en_US
dc.format.extent300975 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers; Springer Science+Business Mediaen_US
dc.subject.otherMedicine & Public Healthen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.subject.otherOncologyen_US
dc.subject.otherAclacinomycin Aen_US
dc.subject.otherMultiple Myelomaen_US
dc.titleAclacinomycin A in the treatment of multiple myeloma: A Southwest Oncology Group studyen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelRadiologyen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbsecondlevelChemical Engineeringen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.subject.hlbtoplevelEngineeringen_US
dc.subject.hlbtoplevelScienceen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan Medical Center, USAen_US
dc.contributor.affiliationotherWayne State University School of Medicine, USAen_US
dc.contributor.affiliationotherSouthwest Oncology Group Biostatistical Center, Seattleen_US
dc.contributor.affiliationotherMidwest CCOP, USAen_US
dc.contributor.affiliationotherArkansas CCOP, USAen_US
dc.contributor.affiliationotherColumbus CCOP, USAen_US
dc.contributor.affiliationotherScott and White Clinic, USAen_US
dc.contributor.affiliationotherUniversity of Oregon Health Science Center, USAen_US
dc.contributor.affiliationotherUniversity of Arizona Cancer Center, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid2188925en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/45336/1/10637_2004_Article_BF00216933.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/BF00216933en_US
dc.identifier.sourceInvestigational New Drugsen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
10637_2004_Article_BF00216933.pdf
Size:
293.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.